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Considerable decrease of TGF-β (p<<0,01), VEGF (p<0,01) and bFGF 
(p<<0,01) in serum was observed following neoadjuvant therapy, with 
no signiﬁcant changes in TIMP-1 and CD95L levels. In serum samples 
collected directly after tumor resection signiﬁcant drop-down of bFGF 
(p<<0,001) continued, while VEGF levels increased (p<0,001), TGF- β 
levels didn’t change and continued to be lower than before therapy 
(p<0,01). As previously, tumor resection didn’t affect TIMP-1 and 
CD95L. Serum levels of VEGF and CD95L as well as CD95L and 
TIMP-1 correlated well before (r=0,36, p<0,05 and r=0,48, p<0,001) 
and after (r=0,35;r=0,39, p<0,05) neoadjuvant therapy. Similar rela-
tion was observed for TGF-βand ﬁbrinogen as well as ﬁbrinogen and 
TIMP-1 before (r=0,499;r=0,41 p<<0,01) and after (r=-0,44;r=0,40, 
p<0,01) surgery. As expected levels of TGF- β, TIMP-1 and bFGF 
were signiﬁcantly higher in excissed tumor than in normal lung tissue 
(p<0,001), while no differences in VEGF and CD95L content were 
demonstrated. Neoadjuvant therapy considerably affected cytokines 
regulating tumor growth: VEGF, bFGF, TGF-β while serum markers 
of apoptosis CD95L or local tumour invasiveness TIMP-1 were not 
affected. Postoperative changes of growth factors might be due to the 
tumor resection and wound healing. 
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What is the standard platinium-derivative based-chemotherapy 
for advanced or metastatic NSCLC: a 10-years trial comparing 
cisplatin (C) and carboplatin (Ca) in combination with gemcitabine 
(G)
Clemente, Susana; Barradas, Pedro; Alves, Paula; Cristóvão, 
Margarida; Costa, Agostinho; Melo, Maria J. 
Hospital Pulido Valente, Lisboa, Portugal
Objectives: to compare survival results obtained at our unit during a 
10-year-time period (1997-2006) with the combinations CG and CaG 
in the treatment of advanced NSCLC patients (pts), and try to answer 
some doubts concerning the balance between efﬁcacy (response and 
survival) and toxicity of these two combinations.
Patients and Methods: 608 pts (stage IIIB -282 IV- 324 were treated 
in this period (CG - 305; CaG - 303). Treatment schedules were: CG (C 
- 80 mg/m2 d1 + G 1000mg d1 and 8 each 3 weeks); CaG (Ca - AUC 
5 d1 + G - 1000mg/m2 d1 and 8 each 3 weeks). Groups were well bal-
anced in which concerns all signiﬁcant prognostic factors to survival.
Baseline and pos-CT characteristics were compared between groups 
using a 2-way-Anova analysis, OOR response rate and toxicities were 
compared with Fisher’s exact test; in order to compare survival curves 
and to estimate hazard ratios and respective CI we used a Cox propor-
tional hazards model stratiﬁed for stage and adjusted for prognostic 
variables.
Results: With a median follow-up of 61 months, more than 88% were 
uncensored (85% for CG and 90% for CaG), OOR is higher for CG 
(41.8% - 95%CI 34.9- 51.1) than for CaG (29.4% - 95%CI 23.2-35.6 
p=0.0034). This clinical response is in line with Cyfra 21-1 median 
drop (-32.7% for CG and - 7.1% for CaG p=0.0028). Comparison of 
median survival beneﬁts CG (overall 10.2 vs. 8.1 mo p=.00006; stage 
IIIB 14.2 vs. 9.9 p=.00029; stage IV 9.6 vs. 7.7 p=0.022). Differences 
in IFD were even more signiﬁcant (overall - CG 6.2 mo vs. CaG 4.3 
p<.000001.) Survival-rates were similarly higher for CG. Haematologi-
cal toxicity was similar for both treatments with the exception of an 
excess of grade 3 and 4 thrombocytopenia for CaG. Few signiﬁcant 
non-haematological side effects were detected. Seven toxic deaths (3 
CG and 4 CaG were reported).
Conclusions: the result of our 10-year study makes clear that CG 
combination is more effective than CaG in which concerns response 
rate, IFD and survival. Haematological toxicity is similar between 
groups, except for thrombocytopenia, more frequent with carboplatin-
based chemotherapy. Consistency of results (response, decrease of 
serum cyfra 21-1 and survival) obtained with the CG association in this 
10-year study together with moderate toxicity, points clearly to this CT 
treatment as the standard for pts with advanced or metastatic NSCLC.
P2-249 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4 
A Phase I Trial of ABT-751 and carboplatin in patients with 
previously treated non-small cell lung cancer
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Non-small cell lung cancer (NSCLC) is the leading cause of cancer 
mortality for men and women in the United States. More effective 
treatments are needed to prolong survival and improve quality of 
life. Platin-containing chemotherapy doublets are commonly used in 
NSCLC treatment. ABT-751 is a novel oral anti-microtubule agent 
targeting the colchicine binding site. As single agent, it was well-toler-
ated and showed a preliminary signal of activity in previously treated 
NSCLC. In vivo studies demonstrated additive activity between ABT-
751 and cisplatin in a NSCLC xenograft model.
A phase I trial of ABT-751 and carboplatin was conducted in patients 
with advanced previously treated NSCLC. Primary objective was to 
determine the maximum tolerated dose (MTD). Secondary objec-
tives were evaluation of toxicities, efﬁcacy, and surrogate markers of 
response (cell cycle changes and cyclin D1 expression) in buccal swabs 
from patients at the phase II dose. Four dose levels were studied - 1: 
ABT-751 100 mg bid, carboplatin AUC 4.5; 2: ABT-751 125 mg bid, 
carboplatin AUC 4.5; 3: ABT-751 125 mg bid, carboplatin AUC 6; 4: 
ABT-751 150 mg bid, carboplatin AUC 6. ABT-751 was taken orally 
twice a day for 7 days in a 21-day cycle, carboplatin was administered 
intravenously on day 4 during cycle 1 to allow for pharmacokinetic 
analysis, and on day 1 of subsequent cycles. Rapid dose escalation was 
used for the ﬁrst 3 dose levels followed by cohorts of at least 3 patients 
for the remaining dose levels.
Thirteen patients were enrolled, twelve patients completed one cycle of 
therapy and were evaluable for toxicities. All patients were previously 
treated with a carboplatin-containing regimen. All patients had stage IV 
NSCLC, median age was 62 years (range 46-73), 5 were women, 2 pa-
tients had Karnofsky performance score (KPS) 90, the rest had KPS 80. 
Seven patients had one and 5 patients had 2 prior therapies. A median 
of 2.5 (1-4) cycles was administered. Dose-limiting toxicities (DLTs) 
were assessed at the end of cycle one. Grade 3 fatigue and grade 4 
thrombocytopenia and neutropenia were observed in 2/5 patients 
on dose level 4. Common grade 2 toxicities were constipation and 
peripheral sensory neuropathy (levels 2-4). MTD was dose level 3. Ten 
patients were evaluable for response, 2 had partial responses lasting 14 
and 28 weeks (levels 2 and 4, both had one prior therapy), 4 had stable 
disease, 4 had disease progression. Median time to progression was 13 
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weeks (5-31). Plasma pharmacokinetic analyses and pharmacodynamic 
analyses on buccal swabs are being performed.
The recommended phase II doses are ABT-751 125 mg twice daily for 
7 days and carboplatin AUC 6 on a 21-day cycle. This regimen is well 
tolerated and shows preliminary evidence of activity for previously 
treated NSCLC.
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A Phase II Study of Gleevec (Imatinib Mesylate) Plus Taxotere 
(Docetaxel) in Patients with Advanced Non-Small Cell Lung 
Cancer 
Eckardt, John R.; Schmidt, Ann; M. White, Leonard A. Jr.; Greco, 
Alfred O.; Sjak-Shie, Nelida N. 
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Background: Docetaxel has been shown to improve overall survival in 
patients with recurrent NSCLC. Pre-clinical data suggests synergistic 
activity with the combination of docetaxel and imatinib. Paul Matthew, 
et al demonstrated the safety of this combination in the MD Anderson 
trial “Targeting the platelet-derived growth factor receptor in androgen-
independent prostate cancer.” Therefore this combination was admin-
istered to patients with recurrent NSCLC to determine overall response 
rate. 
Methods: This is a phase II study of the combination of Taxotere and 
Gleevec in refractory NSCLC to determine tumor activity, toxicity and 
recommendations for further studies of this combination. Patients must 
have received at least one prior regimen and experienced recurrence or 
have been refractory to the initial treatment. Taxotere was administered 
at 30 mg/M2 on a weekly schedule for 3 weeks followed by one week 
rest. Gleevec was administered at a starting dose of 600 mg daily. Dose 
modiﬁcations to address toxicity were built in to the protocol. 
Results: To date, a total of 10 patients have been enrolled on this study. 
Seven male and 3 female with a median age of 66 years (range 58 - 74). 
A total of 26 cycles were delivered to 10 patients (mean = 3).
Four patients experienced fatal adverse events while on study. Two 
with a non-study related fatal MI (both with history of heart disease). 
One patient developed GI perforation not related to study (history 
of ischemic bowel disease). One patient suffered a fatal pulmonary 
embolus not related to study (history of CAD and peripheral vascular 
disease).
Grade 4 toxicities included periorbital edema (1 pt), pneumonia (2 
pts), diarrhea (1 pt), dehydration (1 pt), dyspnea (1pt), anorexia (1 pt), 
bilateral pleural effusion (1 pt), and neutropenia (2 pts). 
Grade 3 toxicities included hyponatremia, renal failure, hypotension, 
mental status changes, anorexia, azotemia, dyspnea, herpetic esopha-
geal ulcer, pneumonia, cough, neutropenia, shortness of breath, weak-
ness, fatigue, and anemia. 
Results: Responses were minimal. Four of 10 patients received only 
1 cycle. Three of those 4 suffered a fatal adverse event and tumor as-
sessment was not performed. The fourth developed herpetic esophageal 
lesions and was started on 2nd line therapy prior to tumor assessment. 
One patient had stable disease after 2 cycles but progressed after cycle 
3. One patient received 3 cycles, had stable disease after cycle 2 but 
refused additional therapy after cycle 3 due to grade 2 nausea. One 
patient had stable disease after 6 cycles then experienced a fatal pulmo-
nary embolus. An additional patient had a partial response after cycle 4 
but CT after cycle 6 demonstrated progression. Two patients progressed 
after cycle 2. 
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Phase 1/2 study evaluating the safety and efficacy of ABT-751 in 
combination with docetaxel vs docetaxel alone in subjects with 
advanced or metastatic non-small-cell lung cancer
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Xiangdong1 Xiong, Hao1 Hagey, Anne1 
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Background: ABT-751 is an orally bioavailable sulfonamide that 
binds to the colchicine site on β-tubulin and inhibits polymerization of 
microtubules. Docetaxel (Taxotere®) is an antineoplastic taxoid. Both 
compounds have been evaluated individually in advanced NSCLC 
subjects and in combination in preclinical xenograft models.
Methods: The Phase 1 open-label dose escalation portion of the study 
was designed to determine the maximum tolerated dose (MTD) and 
recommended Phase 2 dose (RPTD) of ABT-751 when administered 
with docetaxel. For each cycle, subjects received 75 mg/m2 docetaxel 
IV on Day 1 and ABT-751 orally QD for 14 consecutive days fol-
lowed by 7 days off drug. Dose levels of ABT-751 began at 200 mg 
and will escalate by 50 mg increments. Pharmacokinetic sampling was 
performed on Day 1 of Cycle 1. The Phase 2 portion of the study was 
designed to determine the effect of ABT-751 plus docetaxel on progres-
sion-free survival. 
Results: The RPTD was determined to be 200 mg of ABT 751 QD for 
14 days. To date, 7 subjects have been accrued into the Phase 1 portion 
of the study, and preliminary safety data are available for 5. One of the 
subjects in the 200 mg cohort experienced a dose-limiting toxicity of 
grade 4 thrombocytopenia. Two subjects experienced an adverse event 
(1 multiple sclerosis and 1 hiccups) rated grade 3 using the Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0. No 
grade 4 or 5 adverse events were reported. Preliminary results indicate 
that the pharmacokinetics of ABT-751 and its glucuronide and sulfate 
metabolites after concomitant administration of a single dose of ABT-
751 (200 mg) with docetaxel were comparable to those after a single 
dose of ABT-751 (200 mg) alone in a previous study.
Pharmacokinetic parameters of ABT-751 after a 200 mg oral dose of 
ABT-751
Pharmacokinetic parameters of ABT-751 after a 200 mg oral dose of ABT-751
 
ABT-751 
With 
Docetaxel
ABT-751 
Alone#
ABT-751 
Glucuro-
nide with 
Docetaxel
ABT-751 
Glucuronide 
Alone#
ABT-751 
Sulfate with 
Docetaxel##
ABT-751 
Sulfate 
Alone#
N 3 23 3 23 3 23
Tmax (h) 2.3 ± 1.5 2.0 ± 1.3 5.0 ± 2.7 4.5 ± 2.2 5.0 ± 2.7 4.0 ± 2.4
Cmax 
(μg/mL) 9.1 ± 5.0 9.1 ± 4.5 6.1 ± 4.3 4.6 ± 1.7 8.0 ± 3.2 7.4 ± 3.2
AUC0-8 
(μg*h/mL) 33.8 ± 15.1 33.0 ± 10.1 30.2 ± 22.5 26.6 ± 10.5 43.6 ± 21.3 39.5 ± 15.0
#Results from Phase 1 Study M01-303 were used as a historical reference.
Conclusions: The RPTD of the combination of ABT-751 and docetaxel 
has been determined. Coadministration of docetaxel with ABT-751 
does not appear to affect the pharmacokinetics of ABT 751.
